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INTRODUCTION
Canine insulinoma is the neoplastic
growth of the Beta cells of the pancreas. In
man 90%of the growths are found to be
benign while in the dog reports say 69-81 %
of the growths are malignant (2,7). A
malignant canine insulinoma denotes a
functional neoplasm secreting excessive
amounts of insulin or what some authors
term inappropriate release of insulin (1).
Cause of death can be from "irreversible
hypoglycemic brain damage" as well as
euthanasia following unsuccessful
management of a vague neurological
disorder or surgical discovery of
malignancy and metastasis. Presenting
signs are often vaguely neurological as well
as intermittent, leading to a slow,
prolonged diagnostic course which
decreases the prognosis accordingly.
Canine insulinoma is often seen in older
dogs, without predisposition to sex. Some
authors report seeing canine insulinoma
over-represented in the Boxer and Terrier
breeds (2,3,13).
PATHOGENESIS AND
CLINICAL SIGNS
Early in the course of the disease, the
unregulated neoplastic outpouring of in-
sulin has the effect of lowering blood
glucose as well as inhibiting hepatic
gluconeogenesis. Clinical signs mayor may
not be present depending on the rate of
decline of blood glucose. Later in the course
of the disease, as the blood glucose begins
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to fall more rapidly, the pituitary-adrenal
axis responds to counter the insulin effects
with 5TH, glucocorticoids, glucagon,
epinephrine, and norepinephrine. As the
disease progresses and the neoplasm in-
creases in size, the pituitary-adrenal axis'
counter measures are exhausted and the
clinical signs once again appear more
prevalent (14). The intermittancy of the
clinical signs makes early diagnosis very
difficult as neurological exams seldom
uncover deficits. As can be seen, it is not
until late in the course of the neoplasia,
when the prognosis is poor, that the clinical
signs become more consistent and severe.
Clinical signs are directly related to
hypoglycemia. It is not the low level of the
blood glucose which causes the signs but
the rate of decrease of blood glucose (7,12).
Many dogs develop a tolerance to low levels
of blood glucose and can remain outwardly
normal with blood glucose levels as low as
30 mg% or less (5). Because the brain does
not depend on insulin to supply it with
glucose, the over supply of insulin leads to
over supply of glucose to most tissues
excluding the brain. While the presented
animal is usually polyphagic and in good
flesh or obese, the brain is literally starving
to death. Most authors agree that
generalized epileptiform seizures are seen
in about 50 % of the cases. If the clinician is
fortunate enough to observe a siezure, it
can be noted that the hypoglycemic seizure
does not closely follow the preictal, ictal,
and postictal phases of epileptic seizures. If
the owners are questioned closely or the
clinicfan is observant certain stimuli can b~
found which preceed most onsets of clinical
signs. These stimuli can be causes of
glucose utilization such as excitement,
exercise, or fasting, or they can be a cause
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of insulin release, such as eating. Other
signs commonly occurring are generalized
muscle weakness, paraparesis, generalized
muscle twitching, disorientation, hysteria,
stupor, coma, opisthotonus, and
polyphagia. It is not uncommon for the
animal to seem perfectly normal between
bouts of clinical signs.
DIAGNOSIS
At one time, completion of Whipple's
Triad was considered diagnostic for canine
insulinoma. Whipple's Triad consists of a
neurological disorder, hypoglycemia, and
reversal of signs upon administration of IV
glucose (12). It is now realized that many
disorders will respond in a similar manner.
These include hypoadrenalism, hypop-
ituitarism, hepatic lipidosis, hepatic
glycogen storage diseases, hepatic
cirrhosis, inanition, cachexia, and even
some large mesodermal extrapancreatic
tumors. The extrapancreatic tumors are
thought to utilize glucose at a rate faster
than can be maintained by
gluconeogenesis, and have been seen as
metastatic mammary carcinomas and
primary pulmonary carcinomas (7,12).
Other conditions, not specifically related to
blood glucose levels, that can easily be
confused with the clinical signs of canine
insulinoma are idiopathic epilepsy, brain
tumor, lead poisoning, canine distemper,
and organic brain lesions, as well as lumbar
and cervical intervertebral disc diseases
(2,7,14).
Hypoglycemia as determined by a fasting
blood glucose test (using the orthotoludine
method) should make the clinician
suspicious of canine insulinoma. Ideally,
the dog should be in a calm, quiet, relaxed
atmosphere when the blood sample is
taken. Quite often the dog is profoundly
hypoglycemic with blood glucose levels
below 50 mg%. On the other hand, a
normal blood glucose level after a 24 hr fast
does not rule out canine insulinoma as
sometimes a 48 hr fast is needed to
demonstrate severe hypoglycemia (7). In
practice 2-3 fasting blood glucose values
less than 40-50 mg% would be justification
to run or advise a glucagon tolerance test.
Organic hypoglycemia must be dif-
ferentiated from functional hypoglycemia, a
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condition sometimes found in hunting dogs
and toy breeds. Functional hypoglycemia is
the result of increased utilization of blood
glucose due to chronic starvation,
malabsorption, liver damage, poisons,
deficient glycogen storage, or high car-
bohydrate diets and is characteristically
temporary in nature. Often the animal is
normal upon presentation to the clinician.
Organic hypoglycemia finds its causes in
over-treated diabetes mellitus, liver
diseases, kidney disease, hypopituitarism,
as well as canine insulinoma (5,14).
Many tests normally used to detect
hypoinsulinism (diabetes mellitus) can also
be used to indicate the hyperinsulinistic
state. Various glucose tolerance tests fall
into this category. Oral administration of
glucose carries the variable of enteric
absorption and blood flow. A high dose of
glucose (~ g/lb) given IV would result in
little rise in blood glucose from samples
taken in the first few hours post injection in
a canine insulinoma dog. As mentioned
above, other hypoglycemic conditions may
react in a similar manner. Because of the
interdependency of endocrine and exocrine
components of the pancreas, the high dose
intravenous glucose tolerance test can be
abnormal in cases of pancreatitis and
pancreatic degeneration, as well as canine
insulinoma (1).
Ideally, a clinician would like to take a
blood sample and determine the level of
insulin in the blood stream. This is possible
using the immunoreactive insulin test. This
test gives a quantitive insulin level, normal
being about 20 uD/m!. Any value above 50-
54 uD/ml is considered abnormal and
diagnostic for canine insulinoma. However,
this differs among private labs. Samples
sent to labs should request a normal value
and/or include blood from a normal dog.
The drawback to this procedure is expense
as well as the availability of facilities
needed to run such a test. Few practices
have sufficient volume to warrant such a
clinical pathology lab. Often, though,
clinicians can make arrangements with area
hospitals to run this and similar tests. In
some cases, the test is run through the
attending veterinarian and in others, the
client deals with the hospital who sends the
results to the veterinarian and the bill to the
client. The latter case seems to be easier for
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the veterinarian, as well as cheaper for the
client.
Some tests must be disqualified on the
basis of side effects or risks involved.
Epinephrine response tests have been used
by some to demonstrate canine insulinoma.
Sympathetic side effects occurring during
the test can be risky in critical cases.
Tolbutamide, a hypoglycemic drug used in
some human diabetics, causes a direct
stimulation of the Beta cells to release
insulin. This results in a profuse outpouring
of insulin in insulinoma dogs lasting up to
18 hours. A profound hypoglycemia is
possible and for that reason the test is
seldom used. The risk here is too great for
hypoglycemic convulsions, coma, and brain
damage due to anoxia.
The test of choice for the clinician would
include such qualities as ease of ad-
ministration, little risk to the patient, and
diagnostic results. The glucagon tolerance
test seems to fulfill these requirements
better than any other test and still be
economical. Glucagon acts to stimulate
hepatic glycogenolysis while directly
stimulating insulin release from the B cells
of the pancreas. This results in a sharp
response with less risk of hypoglycemic
convulsions and coma.
After a 12 hr fast, blood is taken for a
preinjection blood glucose level. Glucagon
is then administered at the rate of 0.03
mg/kg given intravenously. Blood is then
drawn at 5, 15, 30, 45, 60, 90, 120, and 18,0
minutes after the glucagon injection for
blood glucose level determinations (7,8).
Some authors advocate taking blood at 1
and 3 minutes as well to detect a slight dip
in levels before the large rise. Blood
glucose determinations should be run as
samples are taken or at least spun down
and the serum removed. The reason for this
being the blood glucose levels will decrease
at about the rate of 10% per hour due to
utilization of glucose by white blood cells
(5,16).
A dog with normally responsive Beta
cells should have a high blood glucose level
for more than 2 hrs, then slowly decline to
normal levels. A dog with an insulinoma
will respond with a neoplastic outpouring of
insulin, dropping the blood glucose level
below normal in less than 2 hrs and often
leading to a hypoglycemic state. While the
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glucagon tolerance test is not as risky as the
tolbutamide test, glucose should always be
kept ready for intravenous administration
in case of hypoglycemic convulsions or
coma. To aid in the evaluation of the
glucagon tolerance test, a normal dog can
be tested simultaneously to emphasize the
difference in response of the normal versus
the neoplastic Beta cells.
TREATMENT
Treatment of canine insulinoma is often
discouraging. Due to the difficulty in rapid
diagnosis of the condition, it is often too
late in the course of the neoplastic process
for simple excision or successful long term
medical treatment. In that light, accurate
diagnosis is directed toward saving the
owner unneeded expenses rather than
saving the dog.
Dogs that are seen by the clinician in a
seizure or hypoglycemic coma should be
treated with IV 50 % dextrose given to
effect (7, 14). In an emergency or in the
owner's home, table sugar can be used at
the rate of 1 tablespoon/IO lb given orally
(11). Oral treatment is probably only safe in
a dog showing a weakness rather than in a
seizure or comatose state, as compromised
swallowing reflexes would necessitate the
expertise of passing a stomach tube for
sugar administration.
Long term medical treatment of in-
sulinoma is only palliative and will very
rarely result in any sort of cure. It consists
basically of methods of avoiding or
decreasing the stimulation of insulin
release. The diet is gradually changed over
to a high protein, low carbohydrate ration.
Smalls amounts of food should be given
frequently at least four times daily
(3,7,11,14). At times of exercise, high
carbohydrate snacks should be given to
counter balance glucose utilization (11). It
is essential that the client be well aware of
the stimulants of insulin release so that the
risk of unnecessary seizures is decreased.
Glucocorticoid administration is also ad-
visable to enhance gluconeogenesis and
glycogen storage in the liver. Glucocor-
ticoids are also responsible for some minor
amount of peripheral insulin antagonism
(14). Anti-B cell drugs such as alloxin and
streptozotocin are not only difficult to
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obtain but have not been consistently
successful. Side effects to these drugs often
discourage their use (3,7,14). There is some
discussion that alloxin may only be effective
against normal Beta cells rather than
neoplastic Beta cells (2).
Long term medical treatment can often
be successful in prolonging the life of a
canine insulinoma patient. Some thought
must be given to the quality of life of the
patient. The idea of euthanizing a dog that
is normal most of the time can be as un-
settling for the owner as can watching an
old friend going steadily downhill. Ob-
viously, the most satisfactory results lie
somewhere in the middle when the seizures
reach a frequency or severity intolerable to
the owner.
Surgical correction of insulinoma by
complete excision of the neoplastic mass
must be accomplished early in the course of
the neoplasia as the majority readily
metastasize. Metastatic lesions can be
found in the regional lymph nodes, liver,
mesentery and omentum. To complicate
matters, some forms of canine insulinomas
are diffusely spread throughout the pan-
creas and are difficult to visualize at
surgery. Some authors report a higher
incidence of neoplasia in the right or
duodenal lobe of the pancreas while others
insist that no such prevalence exists
(2,7, 13). The next logical step at surgery
would be to remove the entire pancreas.
Before this is done it is best to consider
having the owner aware of the cost and
trouble of maintaining a dog on insulin and
pancreatic enzymes for life. The success of
this procedure is dependent on the lack of
metastasis. Persistent post-operative
hypoglycemia can be considered indicative
of metastatic lesions (13).
Because idiopathic hyperthermia has
been encountered postoperatively, it is
advisable to administer preoperative
glucocorticoids prophylactically (3, 7,13).
Also, because sugical handling of the
pancreas is associated with insulin release,
10% dextrose fluids should be ready to
administer during surgery (2,3,7). If the
whole pancreas is not removed, it is a good
idea to treat postoperatively for pan-
creatitis, as signs attributable to this are
often seen after surgical manipulation of
the organ (2,3,7). Postoperative monitoring
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can be as extensive as daily levels of blood
glucose, serum potassium, amylase, lipase,
and BUN. These can later be tapered down
to monthly determinations of fasting blood
glucose if the patient recovers uneventfully
(2,7).
CASE REPORTS
Case One
Trixi, a female, eleven year old, terrier
type dog was admitted to Stange Memorial
Clinic (SMC) with a two year history of
seizures. The seizures had increased in
frequency and were now a daily occurrence.
Anti-convulsive drugs (Myelepsin and
Dilantin) prescribed by the referring
veterinarian seemed to decrease the
severity of the seizures but did not
eliminate them. The seizures, when
characterized by the owner, did not fit into
an epileptic pattern. Trixi was described as
becoming drunk-like, staggering, falling,
becoming dyspneic, and showing some
muscle rigidity. The owners felt that Trixi
would often turn to the right before falling,
sometimes crying out or vomiting first.
Physical and neurologic exams revealed
that Trixi was depressed and ataxic; anti-
convulsive medication (Primidone) was
stopped to prevent interference with future
neurologic exams. No neurological deficits
or muscle twitches were detected. Trixi's
mental state was characterized as scared
and timid. Blood drawn for analysis in-
dicated hypoglycemia (48 mg%) and,
although Trixi had been anorexic for three
previous days, a future rerun of parameters
was scheduled. Trixi's appetite improved
and blood was taken for another analysis.
At this time, the blood glucose level was
severely hypoglycemic (21 mg%) and a
glucagon tolerance test was scheduled for
the following day. Throughout Trixi's
hospital confinement the only known
seizure occurred when the owners first left.
Clinicians viewing the seizure felt that it did
not fit an epileptic pattern.
Canine insulinoma was diagnosed from
the results of the glucagon tolerance test
and the owners elected surgery. Prognosis
for a surgical cure was poor due to the
extended duration of clinical signs (2 yrs)
and the chance for metastasis. Preoperative
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procaine penicillin and dexamethasone
(Azium®) were given the day before
surgery. Upon opening the abdominal
cavity and locating the pancreas, the
neoplasm was found to be metastasized to
the liver, omentum, and lymph nodes. The
owners then gave permission for
euthanasia. Because the owners wanted the
body, only a biopsy was taken for
histiopathic study. The study was con-
sistent with gross observations.
Case Two
Missy, a female, six year old, spaniel
type dog was admitted to SMC with the
complaint of periodic fainting, ataxia, and
urinary incontinence. The owners described
three to four "spells" a day of aimless
walking and periods of hyperactivity.
Blood analysis revealed a blood glucose
level of 24 mg%. This low blood glucose
level was in the absence of any "spells."
Results of a glucagon tolerance test were
diagnostic for canine insulinoma and the
owners elected euthanasia. Blood taken
prior to euthanasia was sent to a private
laboratory for an immunoreactive Jnsulin
test to determine the actual level of insulin
in the blood stream. The level was reported
to be 30 mico units/ml, whereas 4 mico
units/ml is considered normal by that
laboratory.
Necropsy revealed an excess of depot fat
consistent with reported polyphagia often
seen with canine insulinoma. The pancreas
was slightly smaller than normal and
contained a firm 4 mm diameter nodule
embedded in the pancreatic tissue. Un-
fortunately, the lobe in which the nodule
was found was not recorded. Histology
revealed a large spherical neoplasm with
architecture resembling islets of
Langerhans. Although unilocular, the
neoplasm was considred to be infiltrating
surrounding pancreatic tissue.
Case Three
Christy, a spayed female, ten year old
Boxer was admitted to SMC with the
complaint of weakness and ataxia after
exercise for the past year. Christy could
usually manage to keep from falling, but
had to struggle.
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Physical exam revealed a trim subject
with no hint of obesity. Blood analysis
revealed a mild hypoglycemia (67 mg%)
and hypercholesterolemia. When run again
the next day, the blood glucose level was
lower (55 mg%). Because the hypoglycemia
and clinical signs were consistent with
insulinoma, a glucagon tolerance test was
run the following day. The results were
diagnostically positive, however the owners
elected not to attempt surgical correction. A
blood sample was sent to a private
laboratory for the immunoreactive insulin
test. It was reported back that insulin levels
were 18 mico units/m!.
After three months the owner reported
that Christy was leading a very normal life.
Due to the winter months, exercise had
been somewhat limited and there had been
a complete absence of weakness and ataxia.
Christy has been on a semi-moist diet all
her life which did not seem to affect clinical
signs at all.
CONCLUSION
Canine insulinoma should be kept in
mind any time a dog is admitted with a
complaint of seizures. A fasting blood
glucose should be mandatory before
automatically putting a dog on anti-
convulsive drugs. A clinician may want to
see three fasting blood glucose levels at 70-
40 mg% or lower before considering a
glucagon tolerance test. Although nine
blood samples are considered to be needed
for an accurate diagnosis, an abbreviated
test would be better than none at all should
economics so dictate. Samples taken at
preinjection, 45 min, 90 min, and 180 min
postinjection may give the most valuable
information. The entire test, though, is
more valid. Early diagnosis is always
sought both to give the patient the best
chance of survival and to save the client
unneeded expense.
At best, the long term prognosis of
canine insulinoma is guarded to poor.
Owner education is an invaluable aid in
deciding what course to follow. Only an
owner who is fully aware of the facts can
make a decision he will not regret or
question in the future.
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